Appointees join Caris’ distinguished clinical and scientific team to accelerate the development and commercialization of innovative precision medicine technologies

IRVING, Tex., May 29, 2014 – Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today that it has assembled leading scientists and clinical experts to join its newly created Scientific Advisory Board (SAB). This team will assist the company with the research, development, strategy and commercialization efforts of its precision medicine offerings.
“As we continue to develop and bring to market innovative medical technologies that we believe will fundamentally change medicine and dramatically improve outcomes, it is incumbent upon us to assemble some of the greatest scientific minds in the world to assist us with our important work,” stated David D. Halbert, Chairman and Chief Executive Officer of Caris Life Sciences. “With this Scientific Advisory Board that George Poste has taken the lead in recruiting — we have done just that.”
George Poste, D.V.M., Ph.D, F.R.C. Path., F.R.S., Vice Chairman of Caris Life Sciences, will serve as Chairman of the SAB. Jonathan Knowles, Ph.D., Vice Chairman of Caris Life Sciences, and Daniel Von Hoff, M.D., FACP, Executive Director, Caris Life Sciences Clinical Research, will also serve on the SAB.
The following members will join them:
Anna Barker, PhD, Director, Transformative Healthcare Networks, Arizona State University, Co-Director, Complex Adaptive Systems Initiative, Arizona State University, Professor, School of Life Sciences, Arizona State University, Former Deputy Director, National Cancer Institute, Former Deputy Director, Strategic Scientific Initiatives, National Cancer Institute
George Demetri, MD, Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Senior Vice President, Experimental Therapeutics, Dana-Farber Cancer Institute, Professor, Department of Medicine, Harvard Medical School
Clay Marsh, MD, Executive Director, Center for Personalized Health Care, The Ohio State University, Vice Dean, and Senior Associate Vice President for Research, College of Medicine, The Ohio State University, Board-of-Directors Member, Personalized Medicine Coalition
Frank McCormick, PhD, FRS, Former Director, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, Chair, Tumor Biology and Cancer Research, Department of Microbiology and Immunology, UCSF, Founder and Chief Scientific Officer, Onyx Pharmaceuticals, Past President, American Association for Cancer Research (AACR) (2012-2013)
William N. Harwin, MD, Founder and President, Florida Cancer Specialists & Research Institute, Past President, Florida Society of Clinical Oncology
John Quackenbush, PhD, Professor, Computational Biology and Bioinformatics, Harvard School of Public Health, Professor, Cancer Biology, Dana-Farber Cancer Institute, Professor, Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Director, Center for Cancer Computational Biology, Dana-Farber Cancer Institute, CEO, GenoSpace, Editor-in-Chief, Genomics
Leonard Sender, MD, Director, Clinical Operations and Program Development, Chao Family Comprehensive Cancer Center, University of California, Irvine (UCI), Division Chief, Pediatric Oncology, Chao Family Comprehensive Cancer Center, UCI; Clinical Professor, School of Medicine, UCI
Lee Schwartzberg, MD, FACP, President and Chief Medical Officer, The West Clinic; Division Chief, Hematology Oncology, The University of Tennessee Health Science Center; Professor, Medicine, The University of Tennessee Health Science Center; Member, NCCN Guidelines Steering Committee; Co-Founder, President and Chief Medical Officer, ACORN Research; Founding Editor-in-Chief, Community Oncology
Jeffrey Vacirca, MD, FACP, CEO/Managing Partner, North Shore Hematology Oncology Associates, Clinical Assistant Professor, Medicine, University Hospital at Stony Brook
Nick Vogelzang, MD, Chair and Medical Director, Developmental Therapeutics Committee, US Oncology Research, Co-Chair, Genitourinary Committee, US Oncology Research, Former Director, Nevada Cancer Institute
“The caliber of these Scientific Advisory Board members will help Caris Life Sciences continue to play a leadership role in the complex, technical, clinical, computational, regulatory and reimbursement landscape that will impact the innovation and adoption of precision medicine,” stated SAB Chairman, George Poste.
A more in-depth bio for each of the SAB members may be found at
www.carislifesciences.com/caris-scientific-advisory-board.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry’s first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient’s cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.
Media Inquiries:
David Patti
JFK Communications
dpatti@jfkhealth.com
609-456-0822